Core Insights - Sonnet BioTherapeutics is advancing its proprietary Antibody Drug Conjugate (ADC) platform designed to address technical challenges associated with ADCs, aiming to enhance value for cancer patients [2][3] - The initial proof-of-concept ADC construct, SON-5010, demonstrated similar efficacy to Kadcyla and trastuzumab-MMAE in preclinical studies, indicating its potential in cancer treatment [1][3] ADC Platform Development - The ADC platform utilizes a flexible payload capacity and controllable drug-antibody ratios (DAR), allowing for the creation of various ADC candidates [2][3] - The platform is differentiated by its stable structural integrity, extended conjugation site flexibility, and potential for enhanced tumor penetration [2][3] SON-5010 Details - SON-5010 is produced through a two-step process involving the expression and purification of targeting scaffold and payload domains, followed by chemical linkage [2][3] - In vivo comparisons showed that SON-5010 achieved similar tumor reduction activity to Kadcyla without detectable toxicity in a mouse model [3] Strategic Partnerships and Future Plans - The company is seeking value-driven discovery partnerships to further develop its ADC candidates [2][3] - Sonnet plans to continue global prosecution of its intellectual property related to the ADC platform while exploring collaboration opportunities [3] Company Overview - Sonnet BioTherapeutics focuses on oncology and has developed the FHAB (Fully Human Albumin-Binding) technology for targeted biologic drugs [5] - The lead program, SON-1010, is in development for advanced solid tumors and is being evaluated in a Phase 1/2a study in combination with Roche's atezolizumab [5]
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates